FDA Wants Comments on Reporting Vaccine Goofs in Factories
Published Date: 9/16/2026
Notice
Summary
The FDA is asking for public feedback on a plan to keep track of problems during the making of biological products like vaccines and human tissues. This helps make sure these products stay safe and effective for everyone. If you’re involved in making or selling these products, you’ll want to know about the new reporting rules and get your comments in by October 16, 2026.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 2 costs, 1 mixed.
45-Day Deviation Reporting Requirement
If you manufacture biological products, human blood and blood components, operate a registered blood establishment, or run a transfusion service, you must report biological product deviations using Form FDA 3486. The rule requires reports to be submitted to CBER or CDER “as soon as possible” but no later than 45 calendar days after you learn of a reportable event.
Estimated Annual Reporting Burden Increased
FDA estimates total annual responses of 17,818 and total annual burden of 34,191 hours for Form FDA 3486/3486A reporting. FDA states this reflects an overall increase of approximately 2,642 responses and 4,612 hours compared to prior estimates, largely from Sec. 606.171 reports (16,277 responses; 32,554 hours).
Electronic Filing and Addendum Details
CBER accepts electronic submissions of Form FDA 3486 and has a web-based addendum (Form FDA 3486A) to collect extra recall-related details; CDER does not currently accept electronic filings. CBER estimates 5 percent of BPD reports to CBER need the addendum, and the addendum takes about 15 minutes (0.25 hours) to complete.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-18945, Crystalline Silicon Photovoltaic Cells, Whether or Not Assembled Into Modules From India: Final Affirmative Determination of Sales at Less Than Fair Value, and Final Affirmative Determination of Critical Circumstances, In Part
The U.S. Department of Commerce found that solar cells from India are being sold in the U.S. for less than their fair price. Starting September 16, 2026, this means importers might face extra duties to keep things fair for American businesses. This decision covers sales from July 2024 to June 2025 and aims to protect the U.S. solar market from unfair pricing.
Next: 2026-18947, Crystalline Silicon Photovoltaic Cells, Whether or Not Assembled Into Modules, From India: Final Affirmative Countervailing Duty Determination and the Final Affirmative Critical Circumstances Determination, in Part
The U.S. Department of Commerce found that Indian makers of solar cells are getting unfair government help, so they’re adding extra taxes on these imports starting September 16, 2026. This means companies importing these solar cells from India will pay more, helping U.S. solar businesses compete fairly. The investigation covered April 2024 to March 2025 and aims to keep the playing field level.